Global AI-Assisted CAR-T Target Discovery Service Market Strategic Research Report

Scope of the Report

The global AI-Assisted CAR-T Target Discovery Service market size is predicted to grow from US$ 93.91 million in 2025 to US$ 367 million in 2032; it is expected to grow at a CAGR of 21.3% from 2026 to 2032.

AI-assisted CAR-T target discovery services support the early stages of CAR-T research and development by applying machine learning, knowledge graphs, single-cell and spatial omics, integrated multi-omics, and functional screening data to identify and prioritize druggable cell-surface antigens or regulatory targets from disease samples. Deliverables typically include candidate target packages covering expression specificity, normal-tissue risk, antigen heterogeneity, off-target potential, and in vitro or in vivo functional validation. Engagements are commonly delivered through project-based, FTE, or co-development models and may extend to dual-target combinations, logic-gated strategies, and CAR design recommendations; the estimated blended gross margin is approximately 58%.

Demand is driven by the shortage of suitable CAR-T targets in solid tumors, antigen escape in hematologic malignancies, and the need to control on-target off-tumor toxicity. As CAR-T programs expand into autoimmune disease, in vivo delivery, and multi-target formats, developers must evaluate target coverage, normal-tissue expression, patient heterogeneity, and resistance pathways at the program-selection stage. Literature review and small-cohort screening alone are increasingly insufficient for these decisions.

The service model is moving from single-layer transcriptomic analysis toward integrated modeling of patient-derived single-cell data, spatial omics, surface proteomics, functional screens, and biomedical knowledge graphs. Computational predictions are increasingly linked to in vitro cell models, organoids, and in vivo validation to create a closed discovery loop. Suppliers include AI-native technology platforms, integrated drug discovery CROs, and specialist cell-therapy service providers, with competition shifting toward data quality, multimodal modeling, explainability, and validation depth.

North America and Europe retain advantages in access to high-quality clinical samples, accumulated single-cell datasets, and innovative CAR-T pipelines, while China is expanding through domestic cell-therapy programs, CRO capacity, and multi-omics infrastructure. Core customers are cell-therapy biotechnology companies, large pharmaceutical groups, and translational research teams. Key risks include sample bias, limited cross-population model generalization, target intellectual-property boundaries, under-detection of low-level normal-tissue expression, and regulatory expectations for traceable algorithmic evidence. Providers with paired tumor-normal datasets, surface-level validation, and multi-target safety assessment capabilities are best positioned for long-term partnerships.

Report Scope

This report presents a comprehensive overview of the global AI-Assisted CAR-T Target Discovery Service market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Data Review and Target Landscape
• AI Target Ranking
• AI Discovery with In Vitro Validation
• AI Discovery with In Vivo Validation
• Integrated Target-to-CAR Development

Segment by Primary Data Modality

• Bulk Molecular Omics
• Single-Cell Omics
• Spatial Omics
• Surface Proteomics
• Functional Screening
• Multimodal Integrated Data

Segment by Target Purpose

• Tumor Cell Recognition Targets
• Tumor Microenvironment Remodeling Targets
• T Cell Fitness Enhancement Targets
• Resistance and Antigen Escape Targets
• Safety Control Targets

Segment by Application

• Hematologic Malignancies
• Solid Tumors
• Autoimmune and Inflammatory Diseases
• Fibrotic and Senescence-Related Diseases
• Infectious Diseases
• Other Indications

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global AI-Assisted CAR-T Target Discovery Service market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Hematologic Malignancies, Solid Tumors, Autoimmune and Inflammatory Diseases evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact